J Z Metcalfe1, S Makumbirofa2, B Makamure2, C Sandy3, W Bara4, P Mason5, P C Hopewell1. 1. Curry International Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA. 2. Biomedical Research & Training Institute, Harare, Zimbabwe. 3. National Tuberculosis Control Program, Harare, Zimbabwe. 4. Harare City Health Department, Harare, Zimbabwe. 5. Biomedical Research & Training Institute, Harare, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Abstract
BACKGROUND: Patients at elevated risk of drug-resistant tuberculosis (TB) are prioritized for Xpert(®) MTB/RIF testing; however, the clinical usefulness of the test in this population is understudied. DESIGN: From November 2011 to June 2014, consecutive out-patients with a history of previous TB in high-density suburbs of Harare, Zimbabwe, were tested using Xpert, solid and liquid culture, and the microscopic observation drug susceptibility assay. Diagnostic accuracy for rifampin (RMP) resistance and time to initiation of second-line regimens were ascertained. The rpoB gene was sequenced in cases with culture-confirmed RMP resistance and genotypic susceptibility. RESULTS: Among 352 retreatment patients, 71 (20%) were RMP-resistant, 98 (28%) RMP-susceptible, 64 (18%) culture-negative/Xpert-positive, and 119 (34%) culture-negative/Xpert-negative. Xpert had a sensitivity of 86% (95%CI 75-93) and a specificity of 98% (95%CI 92-100) for RMP-resistant TB. The positive predictive value of Xpert-determined RMP resistance for multidrug-resistant TB (MDR-TB) was 82% (95%CI 70-91). Of 71 (83%) participants, 59 initiated treatment with second-line drugs, with a median time to treatment initiation of 18 days (IQR 10-44). CONCLUSION: The diagnostic accuracy of Xpert for RMP resistance is high, although the predictive value for MDR-TB was lower than anticipated. Xpert allows for faster initiation of second-line treatment than culture-based drug susceptibility testing under programmatic conditions.
BACKGROUND:Patients at elevated risk of drug-resistant tuberculosis (TB) are prioritized for Xpert(®) MTB/RIF testing; however, the clinical usefulness of the test in this population is understudied. DESIGN: From November 2011 to June 2014, consecutive out-patients with a history of previous TB in high-density suburbs of Harare, Zimbabwe, were tested using Xpert, solid and liquid culture, and the microscopic observation drug susceptibility assay. Diagnostic accuracy for rifampin (RMP) resistance and time to initiation of second-line regimens were ascertained. The rpoB gene was sequenced in cases with culture-confirmed RMP resistance and genotypic susceptibility. RESULTS: Among 352 retreatment patients, 71 (20%) were RMP-resistant, 98 (28%) RMP-susceptible, 64 (18%) culture-negative/Xpert-positive, and 119 (34%) culture-negative/Xpert-negative. Xpert had a sensitivity of 86% (95%CI 75-93) and a specificity of 98% (95%CI 92-100) for RMP-resistant TB. The positive predictive value of Xpert-determined RMP resistance for multidrug-resistant TB (MDR-TB) was 82% (95%CI 70-91). Of 71 (83%) participants, 59 initiated treatment with second-line drugs, with a median time to treatment initiation of 18 days (IQR 10-44). CONCLUSION: The diagnostic accuracy of Xpert for RMP resistance is high, although the predictive value for MDR-TB was lower than anticipated. Xpert allows for faster initiation of second-line treatment than culture-based drug susceptibility testing under programmatic conditions.
Authors: Grant Theron; Jonny Peter; Richard van Zyl-Smit; Hridesh Mishra; Elizabeth Streicher; Samuel Murray; Rodney Dawson; Andrew Whitelaw; Michael Hoelscher; Surendra Sharma; Madhukar Pai; Robin Warren; Keertan Dheda Journal: Am J Respir Crit Care Med Date: 2011-04-14 Impact factor: 21.405
Authors: Sven O Friedrich; Andrea Rachow; Elmar Saathoff; Kasha Singh; Chacha D Mangu; Rodney Dawson; Patrick Pj Phillips; Amour Venter; Anna Bateson; Catharina C Boehme; Norbert Heinrich; Robert D Hunt; Martin J Boeree; Alimuddin Zumla; Timothy D McHugh; Stephen H Gillespie; Andreas H Diacon; Michael Hoelscher Journal: Lancet Respir Med Date: 2013-07-01 Impact factor: 30.700
Authors: John Z Metcalfe; Salome Makumbirofa; Beauty Makamure; Reggie Mutetwa; Renée A Peñaloza; Charles Sandy; Wilbert Bara; Stanley Mungofa; Philip C Hopewell; Peter Mason Journal: Eur Respir J Date: 2015-03-18 Impact factor: 16.671
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: M A Espinal; K Laserson; M Camacho; Z Fusheng; S J Kim; R E Tlali; I Smith; P Suarez; M L Antunes; A G George; N Martin-Casabona; P Simelane; K Weyer; N Binkin; M C Raviglione Journal: Int J Tuberc Lung Dis Date: 2001-10 Impact factor: 2.373
Authors: Dalila Martínez; Gustavo Heudebert; Carlos Seas; German Henostroza; Martin Rodriguez; Carlos Zamudio; Robert M Centor; Cesar Herrera; Eduardo Gotuzzo; Carlos Estrada Journal: PLoS One Date: 2010-08-11 Impact factor: 3.240
Authors: John Z Metcalfe; Peter Mason; Stanley Mungofa; Charles Sandy; Philip C Hopewell Journal: Lancet Infect Dis Date: 2014-09 Impact factor: 25.071
Authors: B Heym; N Honoré; C Truffot-Pernot; A Banerjee; C Schurra; W R Jacobs; J D van Embden; J H Grosset; S T Cole Journal: Lancet Date: 1994-07-30 Impact factor: 79.321
Authors: John Z Metcalfe; Salome Makumbirofa; Beauty Makamure; Charles Sandy; Wilbert Bara; Stanley Mungofa; Philip C Hopewell; Peter Mason Journal: Emerg Infect Dis Date: 2014-01 Impact factor: 6.883
Authors: Nathan Kapata; Martin P Grobusch; Gershom Chongwe; Pascalina Chanda-Kapata; William Ngosa; Mathias Tembo; Shebba Musonda; Patrick Katemangwe; Matthew Bates; Peter Mwaba; Alimuddin Zumla; Frank Cobelens Journal: Infection Date: 2017-08-04 Impact factor: 3.553
Authors: Bertin C Bisimwa; Jean B Nachega; Robin M Warren; Grant Theron; John Z Metcalfe; Maunank Shah; Andreas H Diacon; Nadia A Sam-Agudu; Marcel Yotebieng; André N H Bulabula; Patrick D M C Katoto; Jean-Paul Chirambiza; Rosette Nyota; Freddy M Birembano; Eric M Musafiri; Sifa Byadunia; Esto Bahizire; Michel K Kaswa; Steven Callens; Zacharie M Kashongwe Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079
Authors: David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart Journal: Cochrane Database Syst Rev Date: 2019-06-07
Authors: Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne Journal: Cochrane Database Syst Rev Date: 2021-03-23
Authors: Rouxjeane Venter; Brigitta Derendinger; Margaretha de Vos; Samantha Pillay; Tanya Dolby; John Simpson; Natasha Kitchin; Ashley Ruiters; Paul D van Helden; Robin M Warren; Grant Theron Journal: Sci Rep Date: 2017-11-01 Impact factor: 4.379
Authors: Julia V Ershova; Grigory V Volchenkov; Tatiana R Somova; Tatiana A Kuznetsova; Natalia V Kaunetis; Dorothy Kaminski; Olga V Demikhova; Larisa N Chernousova; Irina A Vasilyeva; Eleanor M Kerr; J Peter Cegielski; Ekaterina V Kurbatova Journal: BMC Infect Dis Date: 2020-07-25 Impact factor: 3.090
Authors: Frederick Haraka; Mwaka Kakolwa; Samuel G Schumacher; Ruvandhi R Nathavitharana; Claudia M Denkinger; Sebastien Gagneux; Klaus Reither; Amanda Ross Journal: Cochrane Database Syst Rev Date: 2021-05-06